Catechol-O-methyltransferase inhibitors

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer et al. (1) in 1961, followed by Barbeau et al. (2) in 1962, and in its ultimately successful form by Cotzias et al. (3) in 1967, still represents the defining landmark in the treatment of PD. This dramatic advance did not materialize out of thin air. It was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

Original languageEnglish (US)
Title of host publicationHandbook of Parkinson's Disease, Fifth Edition
PublisherCRC Press
Pages448-465
Number of pages18
ISBN (Electronic)9781841849096
ISBN (Print)9781841849089
StatePublished - Jan 1 2013
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Catechol-O-methyltransferase inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Pfeiffer, R. (2013). Catechol-O-methyltransferase inhibitors. In Handbook of Parkinson's Disease, Fifth Edition (pp. 448-465). CRC Press.